Bionano Genomics completes head shoulders and then up ?Bionano is a hyper-technological industry that operates at the level of the human genome.
It has developed a platform with an unprecedented ability to detect structural variations in DNA molecules, is active in research for the fight against cancer and other genetic diseases.
It presented excellent results days ago and now a category of big investors has started to direct its capital on it , typical feature in this period where many biotech and pharmaceutical companies seem to receive large inflows of capital ( see related ideas )
The advisor Marketmiracle tells us that thanks to the indicator Mmiracle Viewer decomposes the market to identify the positions on the securities of the various investors.
It generated an input signal on Bionano Genomics at a price of 7.16 usd with a target of 15.08 usd with a potential profit of 110 %.
From the fundamental point of view the company does not shine but it is a characteristic typical of all the companies that operate in the fields in which the investment in search is a necessary and determining part for the own business.
I checked the situation in the chart and it seems that the target can actually be reached after a short accumulation phase that could lead the title to the formation of a bullish head shoulders, the high volatility of the stock could then help to reach such an ambitious target.
Will Bionano Genomics succeed in its intent ? stay tuned....
This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
Biotechnology
I imagine this... probably ... and it’s just the beginning.According to the indicator at the base of the advisor Marketmiracle the CLVS stock is accumulating capitals and is ready for an explosion.
Clovis Oncology is one of the best-selling low-cost titles but produces a drug capable of improving the lives of cancer patients worldwide.
Clearly the money devoted to biotech and pharmaceutical companies during the covid period was directed to vaccine manufacturers but now, that the clouds are clearing up and the covid danger seems to have drifted away, it seems to be heading back to what are the possible cures for the diseases of the century, namely cancer, This is also demonstrated by the recent rise in prices of $AHT, which is a cancer care company ( see related idea)
I imagine a movement of the title as the one indicated in the graph, but I have the feeling that it will only be the beginning, the company a few years ago priced much but much more and its trails are successful as demonstrated by the recent results.
Investing in a society like this is also a way to help medicine and the entire human race..
I did a search on the fundamental analysis sites that I use as a reference and it seems according to their analysts that the current price of Clovis Oncology is absolutely below the right value, which is given around 50 USD
i.imgur.com
I certainly put a chip on Clovis ... I think it’s a great opportunity.
Scrolling at the bottom of this page you will find the advisor Market Miracle who gave a few days ago the input signal on $CLVS.
Mirati Therapeutics good news. The price will start to rise soonI spent about 3 hours researching this company and I will divide my work into 3 parts. Last report, other positive news, and why you shouldn't open long position right now. Enjoy reading.
1) Mirati Therapeutics Reports First Quarter 2021 Financial Results (May 06, 2021)
The most important information:
- Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents - POSITIVE NEWS
- Plan to file an Investigational New Drug (IND) application in 2022 for our investigational KRASG12D inhibitor, MRTX1133 - POSITIVE NEWS
- Presented preclinical data at AACR 2021 on an investigational synthetic lethal methylthioadenosine (MTA) cooperative PRMT5 inhibitor - POSITIVE NEWS
- Research and development expenses for the first quarter of 2021 were $104.1 million, compared to $71.7 million for the same period in 2020. !!!!!!!!!! - IMPORTANT
2) Other positive news (Jun 01, 2021)
- Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
- Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent tiered royalties
3) Why you shouldn't open long position right now
First, there are too many resistance lines at the moment. I doubt that the price will suddenly rise now and break through all resistance lines.
After the May report, the price did not break the white resistance line. Most likely, the next report will raise the price and in my opinion, there is a good chance that it will end the bear market this year.
AbCellera Biologics Inc 🧙AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes, and analyzes antibody responses to engineer new antibody drug candidates for its partners.
If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
Protara Therapeutics Inc 🧙Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
Atreca Inc - It's time to load up. 🧙Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.
-20%
If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
If good for Bill Gates good for us 🧙Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
ACADIA Pharmaceuticals Inc 🧙Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
$BCTX PT 4-4.50BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Is CRSP trading in an Ascending Triangle?It appears as though CRSP is potentially bottoming out and forming an Ascending Triangle pattern.
On the DMI there's been a bullish twist where I have placed the blue downward pointing finger.
On the KST there's been a bullish cross where I have placed the blue check mark and upon back-testing the red line we've seen a bullish bounce where another check mark.
MOTS Should have a nice bounce from hereLikely around a 40% upside potential, Take profit around 1.4$
Blue line is normal trendline support
Red line is Log chart support
Take profit is 0.5 - 0.618 Fib of previous bounce
IFRX Technical Analysis 🧙InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
CFRX a great risks/reward ratio! 🧙ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
BIIB has incoming Golden Cross, rising past support zone?Hi. In this 1D chart I've marked an impending Golden Cross: the point where a MA 56 is very likely to cross a MA 224 upwards.
With this I've also plotted out a Resistance zone and a Support zone. The price has just entered the Resistance zone but instead of turning back this time the momentum of the Golden Cross should push it past the Resistance zone.
I've also included two example trades. One has its SL placed on the price of the Golden Cross and then given a ratio of two to make a reasonable TP.
The other has its SL placed on the top line of the Support zone and given a ratio of 1.75 to make a more conservative long position and keep the TP within a reasonable price.
Thank you. Please, if you have any thoughts or comments do leave them below and I would gladly discuss or adjust my interpretations and methods with you.
This does not constitute financial advice. Any projected prices, even if explicitly stated, are made with intent to discuss the symbol and potential interpretations. Any trades shown or mentioned are examples and neither recommendations or mandates.
Anti-aging biotech is looking super juicy meow meow style!I don't invest in Pharma, and this isn't Pharma! As I understand it, the company is making implants to help counter the aging process. Very future, very cool!
I think this could be a very good week for this stock!
As always, this is not investment advice!
MVMD — Target of shoddy short hit piece by anonymous SA authorThis is a very similar setup to my earlier EXRO call where an anonymous author calling him/herself “Mariner Research Group” put together a shoddy “short thesis” that was quite frankly garbage. It would not surprise me if this “Night Research Group” is the exact same person. Same quality of work, same hastily put together WordPress website with no contact info other than email and no names of who is behind it. Same terrible track record where none of the previous price targets have been reached. Same low follower count.
From the technical perspective, MVMD is oversold on the hourly and is approaching oversold territory on the daily chart . .95 gap was filled and support was found at the .96 Fibonacci line. If support holds, it will start forming a bullish Double Bottom pattern. There’s also a gap at 1.10 up above. Decent risk/reward but stop loss is not a bad idea, IMO.
Recognized R&D Pioneers in Anti-Inflammatory TherapeuticsThe founding team members at 180 Life Sciences Corp. (NASDAQ: ATNF) are the recognized pioneers of research and development in anti-inflammatory therapeutics.
180 Life Sciences is a clinical-stage biotechnology company that brings together the expertise of world-renowned scientists to develop and test novel treatments for inflammation and is currently working in both preclinical and clinical studies.
finance.yahoo.com
$OI to join S&P SmallCap 600 on March 30Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, March 30.
finance.yahoo.com
$APOP and Quoin Pharmaceuticals Announce Strategic MergerCellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger
Cellect shareholders to retain 25% of the combined Company pre-funding
Quoin has secured $25 million in committed equity funding from Altium Capital, a highly regarded institutional healthcare investor.
Quoin has also negotiated an $18.5 million venture loan from a leading U.S. commercial bank.
Completion of the merger is subject to approval of the Cellect and Quoin shareholders and certain other conditions and is expected to close by the end of the second quarter of 2021.
Why $IMMP soared in December case studyFirst time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy
Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo.
Statistically significant OS benefit in efti group observed in pre-defined patient groups:
+7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age
+9.4 months survival benefit (median of 22.4 vs. 12.9 months, 74% longer) from efti with chemotherapy for patients with a low starting monocyte count
Statistically significant increase in CD8 T cells in patients treated with efti plus chemotherapy, correlated with prolonged OS, indicating pharmacodynamic activity and proof of concept of efti’s mode of action
Collection of OS data ongoing, with final data expected to be reported mid 2021
finance.yahoo.com
$PRQR Announces Positive Results from Clinical Trial of QR-421aProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)
QR-421a observed to be well tolerated with no serious adverse events reported
Two pivotal Phase 2/3 trials are expected to start by the end of 2021
finance.yahoo.com